Involvement of human cytochrome P450 3A4 in reduced haloperidol oxidation

European Journal of Clinical Pharmacology

Volumn 54, Issue 3, 1998, Pages 253-259

  Kudo, S ^a   Odomi, M ^a  

^a OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

CYP3A4; Haloperidol

Indexed keywords

8 HYDROXYCARTEOLOL; BIPERIDEN; CARTEOLOL; CYTOCHROME P450 3 A 4; CYTOCHROME P450 ISOENZYME; HALOPERIDOL; OXYGENASE; QUINIDINE; SPARTEINE; TROLEANDOMYCIN; UNCLASSIFIED DRUG;

ARTICLE; COMPETITIVE INHIBITION; DRUG OXIDATION; HUMAN; HUMAN CELL; MICROSOME; PRIORITY JOURNAL;

ANTI-ARRHYTHMIA AGENTS; ANTI-BACTERIAL AGENTS; ANTIPARKINSON AGENTS; BIOTRANSFORMATION; BIPERIDEN; CARTEOLOL; CELL LINE, TRANSFORMED; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; HALOPERIDOL; HUMANS; HYDROXYLATION; ISOENZYMES; KINETICS; MICROSOMES; MIXED FUNCTION OXYGENASES; OXIDATION-REDUCTION; QUINIDINE; SPARTEINE; TROLEANDOMYCIN;

EID: 0031834493     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050455     Document Type: Article

References (46)

1. Forsman A, Larsson M (1978) Metabolism of haloperidol. Curr Ther Res 24: 567-568
2. Pape BE (1981) Isolation and identification of a metabolite of haloperidol. J Anal Toxicol 5: 113-117
3. Forsman A, Folsch G, Larsson M, Ohman R (1977) On the metabolism of haloperidol in man. Curr Ther Res 21: 606-617
4. Subramanyam B, Rollema H, Woolf T, Castagnoli N Jr (1990) Identification of a potentially neurotoxic pyridinium metabolite of haloperidol in rats. Biochem Biophys Res Commun 166: 238-244
5. Subramanyam B, Woolf T, Castagnoli N Jr (1991) Studies on the in vitro conversion of haloperidol to a potentially neurotoxic pyridinium metabolite. Chem Res Toxicol 4: 123-128
6. Eyles DW, McLennan HR, Jones A, McGrath JJ, Stedman TJ, Pond SM (1994) Quantitative analysis of two pyridinium metabolites of haloperidol in patients with schizophrenia. Clin Pharmacol Ther 56: 512-520
7. Eyles DW, McGrath JJ, Pond SM (1996) Formation of pyridinium species of haloperidol in human liver and brain. Psychopharmacology 125: 214-219
8. Oida T, Terauchi Y, Voshida K, Kagemoto A, Sekine Y (1989) Use of antisera in the isolation of human specific conjugates of haloperidol. Xenobiotica 19: 781-793
9. Eyles DW, Stedman TJ, Pond SM (1994) Nonlinear relationship between circulating concentrations of reduced haloperidol and haloperidol: evaluation of possible mechanisms. Psychopharmacology 116: 161-166
10. Inaba T, Kovacs J (1989) Haloperidol reductase in human and guinea pig livers. Drug Metab Dispos 17: 330-333
11. Inaba T, Kalow W, Someya T, Takahashi S, Cheung SW, Tang SW (1989) Haloperidol reduction can be assayed in human red blood cells. Can J Physiol Pharmacol 67: 1468-1469
12. Korpi ER, Kleinman JE, Costakos DT, Linnoila M, Wyatt RJ (1984) Reduced haloperidol in the post-mortem brains of haloperidol-treated patients. Psychiatry Res 11: 259-269
13. Midha KK, Hawes EM, Hubbard JW, Korchinski ED, McKay G (1987) Interconversion between haloperidol and reduced haloperidol in humans. J Clin Psychopharmacol 7: 362-364
14. Chakraborty BS, Hubbard JW, Hawes EM, McKay G, Cooper JK, Gurnsey T, Korchinski ED, Midha KK (1989) Interconversion between haloperidol and reduced haloperidol in healthy volunteers. Eur J Clin Pharmacol 37: 45-48
15. Midha KK, Chakraborty BS, Ganes DA, Hawes EM, Hubbard JW, Keegan DL, Korchinski ED, McKay G (1989) Intersubject variation in the pharmacokinetics of haloperidol and reduced haloperidol. J Clin Psychopharmacol 9: 98-104
16. Chang WH (1992) Reduced haloperidol: a factor in determining the therapeutic benefit of haloperidol treatment? Psychopharmacology 106: 289-296
17. Ereshefsky L, Davis CM, Harrington CA, Jann MW, Browning JL, Saklad SR, Burch NR (1984) Haloperidol and reduced haloperidol plasma levels in selected schizophrenic patients. J Clin Psychopharmacol 4: 138-142
18. Altamura AC, Mauri MC, Cavallaro R, Gorni A (1987) Haloperidol metabolism and antipsychotic effects in schizophrenia. Lancet I: 814-815
19. Tyndale RF, Kalow W, Inaba T (1991) Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase). Br J Clin Pharmacol 31: 655-660
20. Llerena A, Alm C, Dahl ML, Ekqvist B, Bertilsson L (1992) Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther Drug Monit 14: 92-97
21. Spina E, Ancione M, DiRosa AE, Meduri M, Caputi AP (1992) Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects. Eur J Clin Pharmacol 42: 347-348
22. Young D, Midha KK, Fossler MJ, Hawes EM, Hubbard JW, McKay G, Korchinski ED (1993) Effect of quinidine on the interconversion kinetics between haloperidol and reduced haloperidol in humans: implications for the involvement of cytochrome P450IID6. Eur J Clin Pharmacol 44: 433-438
23. Parkinson A (1996) Biotransformation of xenobiotics. In: Kloassen DD 'Casarett and Doull's Toxicology, the basic science of poisons' (ed), McGraw-Hill, New York, pp 113-186
24. Someya T, Inaba T, Tyndale RF, Tang SW, Takahashi S (1991) Conversion of bromperidol to reduced bromperidol in human liver. Neuropsychopharmacology 5: 177-182
25. Kudo S, Uchida M, Odomi M (1997) Metabolism of carteolol by cDNA-expressed human cytochrome P450. Eur J Clin Pharmacol 52: 479-485
26. Otton SV, Inaba T, Kalow W (1984) Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugs. Life Sci 34: 73-80
27. Gut J, Catin T, Dayers P, Kronbach T, Zanger U, Meyer UA (1986) Debrisoquine sparteine-type polymorphism of drug oxidation. Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol. J Biol Chem 261: 11734-11743
28. Otton SV, Crewe HK, Lennard MS, Tucker GT, Woods HF (1988) Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. J Pharmacol Exp Ther 247: 242-247
29. Guengerich FP, Enoch DM, Blair IA (1986) Oxidation of quinidine by human liver cytochrome P-450. Mol Pharmacol 30: 287-295
30. Otton SV, Inaba T, Mahon WA, Kalow W (1982) In vitro metabolism of sparteine by human liver: competitive inhibition by debrisoquine. Can J Physiol Pharmacol 60, 102-105
31. Tyndale RF, Inaba T, Kalow W (1989) Evidence in humans for variant allozymes of the nondeficient sparteine/debrisoquine monooxygenase (P450IID1) in vitro. Drue Metab Dispos 17: 334-340
32. Nakagawa K, Murakami N, Yoshizaki S, Tominaga M, Mori H, Yabuuchi Y, Shintani S (1974) Derivatives of 3,4-dihydrocarbostyril as β-adrenercic blocking agents. J Med Chem 17: 529-533
33. Yabuuchi Y, Kinoshita D (1974) Cardiovascular studies of 5-(3-tert-butylamino-2-hydroxy)propoxy-3,4-dihydrocarbostyril hydrochloride (OPC-1085), a new potent β-adrenergic blocking agent. Jpn J Pharmacol 24: 853-861
34. 2 and cumene hydroperoxide-supported reactions. Drug Metab Dispos 24: 112-118
35. Pfandl B, Morike K, Winne D, Schareck W, Pfaff UB (1992) Stereoselective inhibition of nortriptyline hydroxylation in man by quinidine. Xenobiotica 22: 721-730
36. Wu D, Otton SV, Morrow P, Inaba T, Kalow W, Sellers EM (1993) Human hepatic cytochrome P450 2D6-like activity in nonhuman primates: catalytic characterization in vitro. J Pharmacol Exp Ther 266: 715-719
37. Minder EI, Meier PJ, Muller HK, Minder C, Meyer UA (1984) Bufuralol metabolism in human liver: a sensitive probe for the debrisoquine-type polymorphism of drug oxidation. Eur J Clin Invest 14: 184-189
38. Kahn GC, Boobis AR, Murray S, Brodie MJ, Davies DS (1982) Assay and characterisation of debrisoquine 4-hydroxylase activity of microsomal fractions of human liver. Br J Clin Pharmacol 13: 637-645
39. Marre F, Fabre G, Lacarelle B, Bourrie M, Catalin J, Berger Y, Rahmani R, Cano JP (1992) Involvement of the cytochrome P-450IID subfamily in minaprine 4-hydroxylation by human hepatic microsomes. Drug Metab Dispos 20: 316-321
40. Appanna G, Tang BK, Muller R, Kalow W (1996) A sensitive method for determination of cytochrome P4502D6 activity in vitro using bupranolol as substrate. Drug Metab Dispos 24: 303-306
41. Inaba T, Jurima M, Mahon WA, Kalow W (1985) In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase. Drug Metab Dispos 13: 443-448
42. Huang MT, Chang RL, Fortner JG, Conney AH (1981) Studies on the mechanism of activation of microsomal benzo(a)pyrene hydroxylation by flavonoids. J Biol Chem 256: 6829-6836
43. Schwab GE, Raucy JL, Johnson EF (1988) Modulation of rabbit and human hepatic cytochrome P-450-catalyzed steroid hydroxylations by α-naphthoflavone. Mol Pharmacol 33: 493-499
44. 1 metabolism in human liver microsomes by naturally occurring flavonoids. Cancer Res. 41: 67-72
45. Anders MW, Gander JE (1979) Acetone enhancement of cumene hydroperoxide supported microsomal aniline hydroxylation. Life Sci 25: 1085-1090
46. Fang J, Baker GB, Silverstone PH, Coutts RT (1997) Involvement of CYP3A4 and 2D6 in the metabolism of haloperidol. Cell Mol Neurobiol 17: 227-233